Literature DB >> 2839603

Characterization of the serological cross-reactivity between glycoproteins of the human immunodeficiency virus and equine infectious anaemia virus.

R C Montelaro1, W G Robey, M D West, C J Issel, P J Fischinger.   

Abstract

The reported serological relatedness between the major glycoproteins of human immunodeficiency virus (HIV gp120) and equine infectious anaemia virus (EIAV gp90) was examined using purified antigens in radioimmunoprecipitation (RIP), radioimmunoassay (RIA) and immunoblot assays with reference serum from acquired immunodeficiency syndrome (AIDS) patients, an anti-gp120 goat serum and EIAV-infected horse serum. To assess the contributions of glycoprotein oligosaccharide and peptide components to any observed reactivities, antigens treated with endoglycosidase F to remove carbohydrate were assayed in parallel with the intact glycoprotein. The results of the experiments indicated that the reactivity observed for each antigen was dependent on the immunoassay employed. The RIP and RIA analyses demonstrated that HIV gp120 is equally reactive with the AIDS patient serum, the goat anti-gp120 serum and the EIAV-infected horse serum, whereas the EIAV gp90 reacted only with the horse serum. In immunoblot assays, the HIV gp120 reacted with AIDS patient serum, but not with the EIAV-infected horse serum. Deglycosylation of the HIV gp120 evidently increased its reactivity with the AIDS patient serum, had no significant effect on its reactivity with the goat antiserum, and essentially abolished its reactivity with the EIAV reference serum. Thus, it appears that the serological cross-reactivity observed between HIV gp120 and sera from EIAV-infected horses can be attributed to the oligosaccharide rather than the peptide components of the viral glycoprotein. These studies also emphasize the necessity of employing several assay procedures in assessing lentivirus antigenicity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2839603     DOI: 10.1099/0022-1317-69-7-1711

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  13 in total

1.  Subpopulations of equine infectious anemia virus Rev coexist in vivo and differ in phenotype.

Authors:  Prasith Baccam; Robert J Thompson; Yuxing Li; Wendy O Sparks; Michael Belshan; Karin S Dorman; Yvonne Wannemuehler; J Lindsay Oaks; James L Cornette; Susan Carpenter
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

2.  Characterization of variable regions in the envelope and S3 open reading frame of equine infectious anemia virus.

Authors:  S Alexandersen; S Carpenter
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

3.  Identification of a hypervariable region in the long terminal repeat of equine infectious anemia virus.

Authors:  S Carpenter; S Alexandersen; M J Long; S Perryman; B Chesebro
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

4.  Change in host cell tropism associated with in vitro replication of equine infectious anemia virus.

Authors:  S Carpenter; B Chesebro
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

5.  Gag protein epitopes recognized by CD4(+) T-helper lymphocytes from equine infectious anemia virus-infected carrier horses.

Authors:  S M Lonning; W Zhang; T C McGuire
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

6.  Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization.

Authors:  J E Hansen; H Clausen; C Nielsen; L S Teglbjaerg; L L Hansen; C M Nielsen; E Dabelsteen; L Mathiesen; S I Hakomori; J O Nielsen
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

7.  Detection and induction of equine infectious anemia virus-specific cytotoxic T-lymphocyte responses by use of recombinant retroviral vectors.

Authors:  S M Lonning; W Zhang; S R Leib; T C McGuire
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

8.  Serological method using recombinant S2 protein to differentiate equine infectious anemia virus (EIAV)-infected and EIAV-vaccinated horses.

Authors:  Sha Jin; Charles J Issel; Ronald C Montelaro
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

9.  Proviral sequences detected by polymerase chain reaction in peripheral blood cells of horses with equine infectious anemia lentivirus.

Authors:  K I O'Rourke; M L Besola; T C McGuire
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

10.  Examination of whether persistently indeterminate human immunodeficiency virus type 1 Western immunoblot reactions are due to serological reactivity with bovine immunodeficiency-like virus.

Authors:  C A Whetstone; K R Sayre; N L Dock; M J VanDerMaaten; J M Miller; E Lillehoj; S S Alexander
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.